Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company's aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company's products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+972-7-32442200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees817
Next Earnings DateN/A
OptionableNot Optionable
Syneron Medical (NASDAQ:ELOS) Frequently Asked Questions
What is Syneron Medical's stock symbol?
Syneron Medical trades on the NASDAQ under the ticker symbol "ELOS."
How were Syneron Medical's earnings last quarter?
Syneron Medical Ltd. (NASDAQ:ELOS) issued its quarterly earnings results on Thursday, August, 4th. The medical equipment provider reported $0.09 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.03. The medical equipment provider earned $75 million during the quarter, compared to analysts' expectations of $75.72 million. The business's quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.07 EPS. View Syneron Medical's Earnings History.
Has Syneron Medical been receiving favorable news coverage?
News headlines about ELOS stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Syneron Medical earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are Syneron Medical's key executives?
Syneron Medical's management team includes the folowing people:
- Shimon Eckhouse Ph.D., Chairman of the Board
- Amit Meridor, Chief Executive Officer
- , Bio & Compensation -
- Hugo Goldman, Chief Financial Officer
- , Bio & Compensation -
- Erik Dowell, Vice President-North America
- William Griffing, Chief Executive Officer - Syneron Candela North America
- Shlomo Alkalay, Chief Operating Officer
- Lisa A. Soderquist, Chief Human Resource Officer
- , Bio & Compensation -
- Robert Ruck, Executive Vice President, Asia Pacific
- Robert Fielitz, Vice President and Managing Director of Europe, Middle East and Africa
- Sarit Soccary Ben-Yochanan, Vice President - Business Development & Strategy
How do I buy shares of Syneron Medical?
Shares of ELOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneron Medical's official website?
How can I contact Syneron Medical?
Syneron Medical's mailing address is Tavor Building 4 P.O. Box 550, YOKNEAM, 2069200, Israel. The medical equipment provider can be reached via phone at +972-7-32442200.
MarketBeat Community Rating for Syneron Medical (NASDAQ ELOS)
MarketBeat's community ratings are surveys of what our community members think about Syneron Medical and other stocks. Vote "Outperform" if you believe ELOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
